Drug Profile
Research programme: fluorinated CNS and cancer therapeutics - Trillium Therapeutics
Alternative Names: FV-082; FV-137; FV-162; FV-214; FV-222; FV-225; FV-281; TTI 281; TTI-2341Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Fluorinov Pharma
- Developer Trillium Therapeutics Inc
- Class Antineoplastics; Neuroprotectants; Small molecules
- Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; Bromodomain and extraterminal domain protein inhibitors; Epidermal growth factor receptor antagonists; Nav1.7 voltage-gated sodium channel modulators; Nav1.8 voltage-gated sodium channel modulators; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Cancer; Cancer pain; CNS disorders; Epilepsy; Glioblastoma; Lung cancer; Multiple myeloma; Non-small cell lung cancer; Pancreatic cancer; Waldenstrom's macroglobulinaemia
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Canada (PO)
- 17 Nov 2021 Trillium Therapeutics Inc has been acquired by Pfizer
- 28 Dec 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (PO)